The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins by Gileadi, Opher et al.
The scientiﬁc impact of the Structural Genomics Consortium:
a protein family and ligand-centered approach
to medically-relevant human proteins
Opher Gileadi Æ Stefan Knapp Æ Wen Hwa Lee Æ Brian D. Marsden Æ
Susanne Mu ¨ller Æ Frank H. Niesen Æ Kathryn L. Kavanagh Æ Linda J. Ball Æ
Frank von Delft Æ Declan A. Doyle Æ Udo C. T. Oppermann Æ Michael Sundstro ¨m
Received: 20 May 2007/Accepted: 22 September 2007/Published online: 12 October 2007
  Springer Science+Business Media B.V. 2007
Abstract As many of the structural genomics centers
have ended their ﬁrst phase of operation, it is a good point
to evaluate the scientiﬁc impact of this endeavour. The
Structural Genomics Consortium (SGC), operating from
three centers across the Atlantic, investigates human
proteins involved in disease processes and proteins from
Plasmodium falciparum and related organisms. We pres-
ent here some of the scientiﬁc output of the Oxford node
of the SGC, where the target areas include protein kina-
ses, phosphatases, oxidoreductases and other metabolic
enzymes, as well as signal transduction proteins. The
SGC ?tul?> has aimed to achieve extensive coverage of
human gene families with a focus on protein–ligand
interactions. The methods employed for effective protein
expression, crystallization and structure determination by
X-ray crystallography are summarized. In addition to the
cumulative impact of accelerated delivery of protein
structures, we demonstrate how family coverage, generic
screening methodology, and the availability of abundant
puriﬁed protein samples, allow a level of discovery that is
difﬁcult to achieve otherwise. The contribution of NMR to
structure determination and protein characterization is
discussed. To make this information available to a wide
scientiﬁc audience, a new tool for disseminating annotated
structural information was created that also represents an
interactive platform allowing for a continuous update of
the annotation by the scientiﬁc community.
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Introduction
The long-term goal of structural genomics (SG) has been
ambitiously deﬁned as ‘‘to make three-dimensional atomic
level structures of most proteins easily obtainable from
knowledge of their corresponding DNA sequences’’ (http://
www.nigms.nih.gov/Initiatives/PSI.htm). Long before this
goal is achieved, the multiple specialized SG projects are
expected to have a signiﬁcant impact on many aspects of the
biological sciences.
The most readily apparent contribution of SG is the
rapid expansion in the number of available protein struc-
tures, derived at a reduced cost because of the efﬁciency of
specialized centers. Proper target selection is critical to
ensure that the structures solved by SG centers are indeed
valuable to the research and industrial community, either
because of the intrinsic interest of the proteins investigated,
or because of the improved mapping of the protein struc-
ture universe, providing homologous structural models.
A second important contribution of SG projects for the
scientiﬁc community is the development of methods for
efﬁcient protein production and structure determination,
which could be adopted in smaller research laboratories to
improve productivity.
O. Gileadi (&)   S. Knapp   W. H. Lee  
B. D. Marsden   S. Mu ¨ller   F. H. Niesen  
K. L. Kavanagh   L. J. Ball   F. von Delft  
D. A. Doyle   U. C. T. Oppermann   M. Sundstro ¨m
Structural Genomics Consortium, Botnar Research Centre,
University of Oxford, Oxford OX3 7LD, UK
e-mail: opher.gileadi@sgc.ox.ac.uk
Present Address:
L. J. Ball
F.M.P., Campus Berlin-Buch, Robert-Roessle-Str. 10, 13125
Berlin, Germany
123
J Struct Funct Genomics (2007) 8:107–119
DOI 10.1007/s10969-007-9027-2Other scientiﬁc deliverables of structural genomics
derive from the scale and nature of the operations, and
include comparative studies on members of protein fami-
lies, identifying determinants of speciﬁcity, deriving
general rules, and improving the capability to predict
protein structure and function from gene sequences.
TheStructuralGenomicsConsortium(SGC),operatingin
the Universities of Oxford and Toronto and the Karolinska
Institute, was initiated in 2003 to address needs of industrial
and academic pharmaceutical research. The SGC investi-
gates human and apicomplexan proteins; the targets are
selected based on their potential as drug targets or involve-
mentindiseaseprocesses.Technologically,theSGCfocuses
on interaction of proteins with small molecules (ligands,
inhibitors, substrates and co-factors), and on coverage of
proteinfamilies.Thisreportprovidesseveralexamplesofthe
impact of research undertaken at the Oxford node of the
SGC, including methodology for high-throughput structure
determination, generic means for ligand screening, selected
examples of insight from speciﬁc structures, insights from
family coverage, and the possibilities resulting from the
availabilityoflargenumbersofpuriﬁedproteinsamples.The
other SGC nodes share the core technologies but investigate
non-overlapping target areas.
Finally, the scientiﬁc impact depends on dissemination
of structural data. We describe a new platform for
distribution of annotated protein structures, which aims at
making this data more meaningful to an audience beyond
the usual users of the PDB.
Methodology
Protein production
Method adaptation and development for structural
genomics involved a change of mindset, no less than
developments in instrumentation, chemistry and computer
software. Industrialization of protein production––applied
to a huge variety of proteins with very divergent chemical
properties––is not straightforward. Yet, extensive work in
several SG centres have led to a convergence to core
procedures, which are widely applicable, and often sufﬁ-
cient to generate puriﬁed proteins, crystals and structures
(Table 1). Where the core protocol fails, additional steps
(e.g., further puriﬁcation, crystal optimization), or alter-
native methods (e.g., different cloning vectors) are applied.
Several features of this protocol have been optimized to
capture a large portion of target proteins. Gene clones have
been predominantly obtained from public and commercial
cDNA libraries. However, gene synthesis may become the
method of choice, allowing to optimize codon frequency,
Table 1 Core protocols employed at the SGC
1. Source of DNA 1. Sequence-veriﬁed cDNA clone collections.
2. Synthetic DNA.
3. RT-PCR, site-directed mutagenesis.
4. Genomic (microbial).
2. Cloning Ligation-independent cloning.
Recombinase-based cloning (e.g., Gateway, InFusion).
3. Expression vectors and hosts T7 promoters, controlled by Lac repressor.
Bacterial vectors N-terminal hexahistidine tag, cleavable by speciﬁc proteases (TEV, Thrombin, C3).
Host strains based on BL21(DE3), often expressing rare-codon tRNAs or chaperone proteins.
4. Eukaryotic expression Bacoluvirus-infected insect cells.
5. Protein expression Rich media, grow at 37 C to mid-log, then induce at low temperature with IPTG.
OR: Similar protocol using minimal medium for Selenomethionine or isotopic labelling.
6. Puriﬁcation Two-step puriﬁcation: Afﬁnity chromatography, Gel ﬁltration, all in high-salt buffers (0.5 M
NaCl). Optional: tag cleavage and re-puriﬁcation.
7. Ligand and buffer screening Thermal denaturation assays are used to screen puriﬁed proteins against 1–10
3 small molecules
and several buffer compositions, to identify stabilizing conditions and potential ligands.
8. Crystalliation Initial coarse screens (2–4 · 96 conditions; 3 protein concentrations each). Vapour diffusion,
sitting drops, imaged by robots but scoring done by humans.
Include ligands identiﬁed from screening or biochemical knowledge to promote crystallization.
Follow-up screens and crystal optimization.
9. Data collection and structure determination Manual or robotic screening of crystals for diffraction properties; data collection in rotating
anode or synchrotron sources.
Phasing: Molecular replacement (95%), experimental phasing using SeMet derivatives,
and MIR.
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123restriction sites, and mRNA structure and to introduce site-
directed mutations. Ligation-independent cloning is a
generic, high-throughput process that can be uniformly
applied regardless of the target gene or the cloning vector.
Short N-terminal fusion tags, including a hexahistidine
sequence and a speciﬁc protease cleavage site, are almost
universally used. It has been widely documented, that lar-
ger fusion tags (e.g., GST, thioredoxin, MBP) can enhance
solubility of proteins that are not soluble when expressed
with a short peptide tag. However, such fusion proteins
have not been widely used in the SGC, since removal of the
tag often leads to loss of solubility.
The standard puriﬁcation protocol is designed to be
widely applicable, and experience has shown that it results
in effective puriﬁcation of a large fraction of proteins
solubly expressed in E. coli. A protein presented for
crystallization must be homogeneous in composition, post-
translational modiﬁcation and oligomeric state; the pres-
ence of protein aggregates may be especially detrimental to
subsequent crystallization. Afﬁnity puriﬁcation of highly-
expressed proteins eliminates most other proteins, while
gel ﬁltration effectively separates different oligomeric
forms of the protein and removes protein aggregates, which
may otherwise promote irreversible aggregation of the
protein preparation. The use of high salt concentration
(typically, 0.5 M NaCl) throughout the puriﬁcation process
seems to reduce protein aggregation and non-speciﬁc
binding of protein contaminants. Tag cleavage followed by
another passage through the afﬁnity column provides a
further generic and highly effective puriﬁcation step, which
removes other proteins that bind adventitiously to the ﬁrst
afﬁnity column. The generic puriﬁcation procedure has
provided in the majority of cases protein of sufﬁcient purity
to achieve crystallization. In most other cases, the generic
procedure could be followed by polishing and protein
modiﬁcation steps to achieve homogeneous preparations.
The greatest barrier to production of human proteins in
bacteria is recovery of soluble protein. Less than 15% of
protein targets yielded detectable levels of soluble protein
when tested as full-length constructs in the SGC, while
more than 80% were expressed as insoluble aggregates.
The key to achieving higher success rates has been the
parallel production of large numbers of truncated con-
structs, often containing a compact protein domain.
Construct design is initially based on domain boundary
analysis, using a number of bioinformatic tools; 3–4 end-
points are designated around each of the predicted termini
of the domain, resulting in 9–16 constructs. We have
consistently found that this approach results in a 4-fold
increase in the number of targets that can be produced as
soluble proteins; a similar impact has been seen on the
production of diffracting crystals, which can be dramati-
cally affected by minute changes in protein termini.
Although not rigorously tested, it is presumed that a protein
construct that is inherently well-behaved (little tendency to
aggregate or denature) will be less dependent on special-
ized conditions for expression and puriﬁcation, and may
crystallize in a wider range of conditions.
Crystallization, crystal screening and data collection
For successful crystallization of a given target, the SGC’s
phase I operation appears to have conﬁrmed that the most
important driver for success is to explore protein diversity
at the crystallization stage. One major form of variation
was discussed above, namely testing multiple constructs of
the target. Equally effective has been setting up co-crys-
tallization with multiple ligands, along with varying
protein concentration in the primary crystallization screens.
At the same time, it appears not to be vital to explore
chemical space extensively for any given protein prepara-
tion; instead, the primary goal of the initial (coarse) screen
can be to identify which preparations are ‘‘crystallizable’’,
and a limited set of coarse screen conditions (*200)
generally seems sufﬁcient. Practically, this requires only
two 96-well crystallization plates, and by setting up three
drops per condition, at different protein-well ratios (in
Greiner 3-drop plates), the protein concentration is simul-
taneously varied. The conditions themselves are derived
from those found to be most successful in other high-
throughput initiatives [1–3], although according to this
‘‘crystallizability’’ philosophy, the exact composition is
probably not important. Naturally, coarse screens do not
always yield high-quality crystals that can produce a
dataset; however, the SGC operation does not rely on these
crystals showing up in coarse screens, and a good optimi-
zation infrastructure is in place.
In practice, this diversity exploration leads to large
numbers of parallel crystallization experiments, presenting
a logistical challenge which, at this scale, can only be met
with an efﬁcient robotics and IT infrastructure. For the
automation, the SGC has been able to exploit the devices
developed on the back of the ﬁrst wave of structural
genomics initiatives, and our investment has been less in
developing the machines, than in integrating them and
implementing experimental best practices. Particular
examples: by minimizing sample requirements with nano-
litre crystallization, the available protein can be used in
more experiments. The large numbers of drops thereby
produced (1.5 million/year) would be practically impossi-
ble to view by eye under the microscope, whereas
automatic drop imaging on a ﬁxed schedule allows images
to be reviewed at leisure at the desk.
Automation has also played an important role in crystal
characterization. An automatic sample changer has been
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vast number of crystals. This allows to rank the crystals for
more careful data collection, especially at the synchrotron,
and to direct further efforts at crystal optimization.
A signiﬁcant saver of upstream efforts has been to
exploit each crystal’s diffraction as efﬁciently as possible,
even those traditionally considered to be marginal or
problematic. Marginal diffractors would include crystals
that are ‘‘very small’’ (\40 lm in longest dimension),
twinned, or have streaky or anisotropic diffraction. The
latter cases generally require the undivided attention of
experienced crystallographers.
Small crystals require an excellent X-ray beam: the PXII
beamline of the Swiss Light Source synchrotron provides a
beam which is reliably small but also well-aligned and very
stable. Most efﬁcient use of the beamline relied on pre-
screening all crystals at the laboratory source for thorough
work prioritization; real-time data processing during data
collection; and close attention to radiation damage of
crystals. It has been crucial to have experienced crystal-
lographers on site. Adherence to these good practices has
been highly productive: of datasets collected on 24-hour
trips to SLS, 66% were used for ﬁnal structures, while 90%
of all depositions relied on synchrotron data. The ability to
extract useful data from marginal crystals has been espe-
cially productive in combination with the protein/ligand
diversity approach of the SGC, as a signiﬁcant fraction of
structures ([50%) could be derived from crystals emerging
from the primary screens, saving the need for further
optimization.
Phasing and structure solution
Due to the family-based approach, for most SGC targets a
homologous structure is already known, and most struc-
tures ([95%) can be phased by molecular replacement
(MR). While this saves signiﬁcant experimental efforts
upstream compared to experimental phasing, by eliminat-
ing the need for selenomethionine-derived protein or heavy
atom soaks, we ﬁnd this does not actually save time
overall, because starting phases from MR are heavily phase
biased. Removing the bias has required many iterations of
careful and incremental model building and reﬁnement by
experienced crystallographers who can see the danger signs
of a poorly-reﬁned model, and know how to deal with it
[4, 5].
The ﬁnal step, namely ﬁnalizing and depositing the
model, is in fact a frequent stalling point, not only in high-
throughput contexts. The reason is that the ﬁnal model is
not merely a result that can be trivially read off a few
measurements, but instead is an interpretation of often
rather noisy data, with a lot of detail that is easy to miss,
where individual errors inﬂuence the clarity in all areas.
Moreover, poor model deﬁnition affects biologically
interesting parts of a structure, and interpreting it becomes
a matter of judgment and using in orthogonal information.
Indeed, the ‘‘ﬁnal’’ model is as much scientiﬁc hypothesis
as result, and depositing the model means signing off on
the hypothesis––which is why it has traditionally been a
bottleneck in structural genomics efforts.
The SGC has used a peer proofreading system combined
with strict timelines to counteract the problem: before
deposition, the structure is reviewed by another crystal-
lographer for errors or alternative interpretations, and
comments passed back to the original reﬁner. The intention
is threefold: First, to introduce quality control on the ﬁnal
output. Second, the reﬁner does not feel compelled to
spend excessive time on the model to ﬂush out the ﬁnal
errors, since she knows it will be checked. Third, by mixing
up reﬁners and proofreaders, over time this should lead to
common interpretations of marginal modeling decisions.
The timelines depend on situation and difﬁculty, but typi-
cally allow two weeks for reﬁnement, a day for
proofreading, and two further days for deposition.
This approach has made it possible to deposit novel
structures at a considerable rate (6 each month from a team
of 6 dedicated and 4–5 occasional crystallographers)
without compromising quality.
Information infrastructure
An efﬁcient laboratory information management system
(LIMS) has been vital to manage not only target tracking,
but also capturing and integrating where possible infor-
mation generated from robotics, as well as capturing
human assessments of experimental outcomes, where these
could be entered via a client (e.g., scoring of crystallization
images).
Fortuitously, the solution we settled on, BeeHive from
Molsoft (http://www.molsoft.com/beehive.html), is in
essence an extremely intuitive database query tool that
enables even inexperienced users to extract information
relevant to their current work––including the simpliﬁcation
of data entry. This is a weak point of many LIMS solutions,
whose focus often evolves around data entry but have very
inﬂexible retrieval mechanisms. This has proved to be a
powerful means of communication between all persons
involved in a project, allowing immediate and error-free
retrieval of ‘‘hard’’ information (e.g., protein sequence,
ligand and buffer conditions and project history), as well as
evaluation and prioritization of crystals and of concurrent
projects.
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One of the major challenges in structural genomics is
identifying the function and evaluating the functional
integrity of the proteins. Examining the physical state of a
protein––by methods such as analytical ultracentrifugation,
chromatography or dynamic light scattering––is valuable
in assessing the prospects for crystallization. In contrast,
speciﬁc activity assays need to be tailored for each protein
class, and may be impractical or impossible when the
activity of the protein is not known. We have implemented
a generic screen, based on the increase in thermal stability
of a protein upon ligand binding. The ﬂuorescent readout is
based on monitoring of protein unfolding using a hydro-
phobicity-sensing dye. Differential Scanning Fluorimetry
(DSF) assays [6–9] are ideal for screening a large number
of compounds for binding to each target protein. Signiﬁ-
cantly, the shift in Tm (the unfolding transition midpoint)
measured by this method is comparable to measurements
obtained by differential scanning calorimetry (DSC), the
well-established standard method for thermal shift mea-
surements. In selected cases, a direct correlation between
Tm shift and binding constants has been observed [8, 10].
Several advantages have been derived from this capa-
bility: First, the identiﬁcation of relatively strong
interacting molecules out of several hundreds of candi-
dates. As detailed below, the compounds discovered in this
manner are then included in crystallization experiments; in
many cases, only protein–ligand complexes yielded dif-
fracting crystals. Secondly, the reactivity proﬁles provide
data on binding selectivity of the protein active site, which
is the most crucial information for drug design; we have
often followed up the results from ligand screens by ana-
lyzing the structures of several protein–ligand complexes.
In parallel, the properties of the protein–ligand interactions
are studied by biophysical methods and by enzyme inhi-
bition studies. Third, such screens have allowed us to
identify ligands or substrates of proteins with unknown
function (sometimes termed ‘‘de-orphanizing’’). Finally,
DSF-based screens can be expanded to explore other
conditions, such as buffer composition that enhance the
stability of a protein. These conditions may then be intro-
duced to improve the outcome of protein puriﬁcation and
crystallization [8].
The limited scale of protein production and other limi-
tations on resources do not allow a full-scale screen as done
in the pharmaceutical industry (10
5 compounds). Rather,
we have assembled smaller family-speciﬁc compound
libraries (10–10
3 compounds each), which can reasonably
be tested against available amounts of protein (*200 lg
for 100 assays). The compound libraries are based on the
scientiﬁc and patent literature; the chemical structure of
prospective compounds is used to search an in-house
compilation of vendor databases to identify potential
sources. Acquisition of desired compounds is not trivial:
not all published compounds, even those appearing in
vendor catalogues, are actually available when required;
alternative vendors, or collaborative sources may then be
accessed. With continuous updating based on current lit-
erature and our own experimental results, these libraries
have allowed to derive binding proﬁles and new insights on
ligand speciﬁcity.
SGC target and biology area selection: relevance for the
treatment of human diseases
For any structural genomic organisation target selection is
an important consideration as it can have a major impact on
the procedures that are implemented during the process of
structure determination. There are a number of approaches
applied by different structural genomics projects to select
targets for structural analysis such as blanket coverage of
an organism’s genome, targets with potential novel folds,
percentage cut off based on sequence identity or total
coverage of selected protein families. The SGC has opted
for the family-based approach with an emphasis on protein
families whose members are important in human health,
disease and are potentially druggable. From our point of
view, the main advantages of this approach are 2-fold.
Firstly, the methods and procedures identiﬁed for one
family member can be applied to another family member
improving everything from expression, solubility, stability,
and puriﬁcation, to crystallisation and structure determi-
nation. Secondly, analysis of the structures from all family
members can reveal additional signiﬁcant information such
as ligand binding site speciﬁcity, conformational dynamics,
understanding of aberrant behaviour of speciﬁc family
members or the converse revealing common structural
properties within all family members.
The availability of high resolution structures constitutes
the foundation for structure-guided drug discovery projects.
In recent years SG has signiﬁcantly increased the number of
human protein structures available for structure-based
design projects [11]. In particular, protein family focused
efforts originating from high-throughput structural biology
projects have contributed to the structural description of a
number of members from human protein families and thus
provided valuable structural and chemical information for
the design of bioactive compounds. In addition, established
expression and crystallization conditions have been used to
generate essential reagents, methodologies and technolo-
gies which have facilitated research projects in academia
and drug discovery programs in industry.
The SGC has focused on providing protein structures to
support drug development and understanding of the
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targets deposited by the SGC (in phase 1), clear disease
relevance has been established for 70% and a further 18%
are likely to be involved in at least one disease. This pattern
holds true for all the human protein families the SGC is
working on. The following sections provide an overview of
the three distinct biological areas selected at the Oxford
site of the SGC.
Biology area I: Structural Genomics of human
metabolic enzymes
Selection of metabolic enzymes as biological target area at
the SGC was based on two distinct features: they are
fundamentally involved in a multitude of human diseases,
including cardiovascular, metabolic diseases or cancer, and
in addition several enzymes constitute possible drug tar-
gets. Emphasis has been given to certain metabolic enzyme
families such as oxidoreductases (mostly short-chain
dehydrogenases/reductases (SDR), medium-chain dehy-
drogenases/reductases (MDR), long-chain dehydrogenases/
reductases, aldehyde dehydrogenases (ALDH), aldo keto
reductases (AKR) and 20oxoglutarate dependent oxygen-
ases (2OGs). In addition, pathways of importance, e.g., in
lipid or amino acid metabolism were selected with a dis-
tribution of about 1:1 between oxidoreductases and other
metabolic enzymes. The target list comprises about 300
metabolic enzymes, and after three years of operation,[60
unique novel structures have been solved. Three points of
importance are highlighted in this review: structural char-
acterization of enzymes shown to be causative of metabolic
inherited diseases, structure determination of drug discov-
ery targets in metabolic diseases such as metabolic
syndrome or osteoporosis, and structure-guided ‘‘de-or-
phanization’’ of insufﬁciently characterized human gene
products or even entire pathways.
Structural basis of inherited metabolic diseases
Genetic defects in enzymes involved in metabolic path-
ways such as amino acid or lipid catabolism are causative
of a whole spectrum of symptoms, including dysmorphol-
ogies, mental retardation, neuropathies or life threatening
situations like fasting induced hypoglycemia [12, 13].
Understanding of molecular causes and possible interven-
tions of inherited metabolic diseases requires besides
biochemical and clinical management a structural template
for explanation of mutational effects.
Thus far the focus has been to a large extent on oxido-
reductases in the area of metabolic diseases. Associated
disorders comprise electron transfer reactions for energy
production (e.g., mitochondrial myopathies), oxidative and
reductive roles in the metabolism of amino acids (e.g.,
hyperprolinemia or branched-chain hydroxyacyl CoA
dehydrogenase defects), fatty acids (e.g., inborn errors in a-
and b-oxidation of short-, medium- or long-chain fatty acid
metabolites), cofactors (e.g., phenylketonuria type 2),
hormones (e.g., male pseudohermaphroditism or adrenal
hyperplasia), mediators (e.g., congestive heart failure) and
lipids (e.g., inborn errors in cholesterol synthesis, CHILD
syndrome, Smitz-Opitz Laemmli syndrome as examples).
The impact of the structural approach is illustrated by the
successful structure determination of phytanoyl-CoA
hydroxylase [14], the major molecular cause of Refsum
disease, a peroxisomal disorder with severe neurological
symptoms. The structure provides a framework to interpret
the majority of the disease causing polymorphic alleles,
and we were able to map those to changes in the active site,
around the Fe
2+ and 2-oxoglutarate binding sites in this
2OG enzyme [14].
Metabolic enzymes as drug targets
Oxidoreductions at speciﬁc positions of lipid hormones
such as steroids selectively alter nuclear receptor binding
properties. Therefore, inhibition of dehydrogenases/reduc-
tases carrying out these reactions selectively inﬂuences
cellular hormone levels and transcriptional responses. This
concept has recently found great attention with the devel-
opment of speciﬁc inhibitors against 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) as a novel drug target in
diabetes and obesity [15–18]. Similar drug development
efforts are underway regulating androgen or estrogen levels
through speciﬁc modulation of distinct hydroxysteroid
dehydrogenases (17b- and 3a-HSDs in cancer, inﬂamma-
tion, osteoporosis, ageing, and autoimmune diseases). We
determined the structure of human 11b-HSD1 in complex
with a clinically relevant inhibitor, carbenoxolone (Wu
et al., unpublished) and have provided a platform for drug
development efforts. Other hydroxysteroid dehydrogenase
structures comprise 17b-HSDs such as types 4, 8, 10, 11
and a novel type 14 (see below), necessary for determi-
nation of off-target activities of compounds directed
against type 1 and 3 17b-HSDs. Other targets of pharma-
ceutical relevance successfully pursued are farnesyl
diphosphate synthase (FDPS) and geranylgeranyl diphos-
phate synthase (GGPS), which are critical in synthesis of
isoprenoids necessary for covalent modiﬁcation of GTP-
ases involved in cell signalling and survival. Crystal
structures of FDPS complexed with nitrogen-containing
bisphosphonates currently used for osteoporosis therapy
allowed a molecular mechanism of action to be postulated
for these drugs [19] (Fig. 1). Furthermore, several
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tiﬁed as novel targets for antibiotic and antiparasite drug
development, and thus allow synchronization with the SGC
Toronto efforts, where an apicomplexan/protozoan SG
program has been established. Thus, structure determina-
tion of related human enzymes will facilitate structure
aided drug design and allow virtual and focused screening
efforts in this emerging disease area.
Deorphanization of metabolic enzymes and pathways
A signiﬁcant proportion of the metabolic enzymes targeted
were at the time of structure determination devoid of
assigned activity or function. High throughput protein
production, structure determination and functional charac-
terization allowed ‘‘deorphanization’’ of unknown
enzymes. We employed ligand screening, enzyme activity
assays, expression and subcellular localization data, as well
as structure determination combined with docking analysis
to describe novel human enzymes. In the absence of co-
crystal structures, interpretation of results from biochemi-
cal assays and compound screening was rationalized by in
silico docking of potential ligands into the active site of the
orphan structures. Analysis of the different docking poses
was correlated with experimental results, allowing direct
visualization of the putative protein–ligand complex. In
this manner we determined a novel 17b-HSD14 [20],
possibly involved in cancer, and a novel type-2 R-hy-
droxybutyrate dehydrogenase, involved in ketone body
utilization [21]. Further emphasis was given on novel
pathways such as mitochondrial fatty acid synthesis. This
recently discovered pathway is important in the synthesis
of lipoic acid, essential for mitochondrial function. Thus
far we have determined three distinct enzymes of this
metabolic route, namely the malonyl transferase (2c2n),
ketoacyl synthase (2c9h) and the enoyl-ACP reductase
(1zsy). These structures represent the only higher eukary-
otic structures thus far available for this pathway. The data
will be instrumental to compare to the multidomain type I
fatty acid synthase, where we recently solved the structure
of the malonyl/acyl transferase domain (2jfk, 2jfd). This
cytosolic enzyme is involved in production of endogenous
fatty acids and lipids, and is discussed as potential target in
metabolic diseases and cancer.
Biology area II: Structural Genomics of
transmembrane receptor signalling pathways
Complete coverage of the14-3-3 protein family
A human protein family that the SGC has completed the
structure determination of all members is the 14-3-3 fam-
ily. This family consists of seven members (b, e, g, c, r, s,
and f) of which r [22, 23], s [24] and f [25] structures were
previously determined. This protein family plays a central
role in many fundamental cellular roles such as cell cycle
control, apotosis, protein trafﬁcking, signal transduction
and stress response [26–28].
Before the structural completion of the 14-3-3 family
most of the structural studies utilised 14-3-3f which pro-
vided details of the conserved peptide binding site [25], the
primary peptide interaction [29, 30] and secondary target
domain interactions [31]. As all of these structures dis-
played similar overall conformations, structurally it was
proposed that 14-3-3s behaved as ‘‘molecular anvils’’ in
that their overall structure remained unchanged whether in
the apo-form or bound to their target protein [32]. The
structure determination of the remaining members allowed
for a family-wide comparative study that revealed another
story with a major emphasis on the ﬂexibility of 14-3-3s
[33]. This was most obviously with the apo-form of 14-3-
3b in which one of the subunits was in a similar confor-
mation to all other 14-3-3 structure while the opposing
monomer displayed a more open conformation for the
peptide binding groove (Fig. 2).
Additional ﬂexibility of 14-3-3 proteins was observed
when all of the family members were superimposed against
one subunit. It became instantly clear that the position of
the second subunit varied between the different 14-3-3
isoforms [33]. This is achieved through the N-terminal
helices that make up the dimeric interface sliding over one
another (Fig. 2). The signiﬁcance of the interface ﬂexibility
is that it allows for the widening or shortening of the dis-
tance between the two peptide binding grooves hence
allowing a 14-3-3 to accommodate structures of varying
Fig. 1 Bisphosphonate binding to human farnesyl diphosphate
synthase. Electron density is shown in green around the clinically
used inhibitor risedronate
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dreds of partners [34–36] this interface ﬂexibility would
provide the necessary structural adaptability to accommo-
date the wide structural range of target proteins.
As all of the human 14-3-3 structures are now known
they allow for a detailed bioinformatic analysis of the 14-3-
3 family. This approach identiﬁed common protein–protein
interaction patches at the subunit interfaces plus two
additional non-speciﬁc protein interaction sites that would
attract and bind the globular structured regions of the target
protein thus providing a mechanism by which the 14-3-3s
can initially attract and then bind a wide range of struc-
turally diverse target proteins [33]. Another more
numerous protein–protein interaction family that was tar-
geted by the SGC are the PDZ domains which have been
implicated in the regulation of drug transporters [37] and
involved in the clustering, targeting and localisation of the
target proteins [38]. These domains bind mostly to C-ter-
minal peptides that fall into two classes: class I peptides are
–(Ser/Thr)–X–U–COO
– while class II peptides are –U–X–
U–COO
– where X represents any amino acid and U rep-
resents any hydrophobic residue [39, 40].
PDZ domains
Initial attempts at structure determination of 18 unique
human PDZ domains resulted in a successful outcome for
only 3 of these targets. To improve our success rate we
took advantage of the family based approach and generated
new expression clones of the remaining 16 targets with
generic class I and II PDZ binding peptides attached to the
C-terminus of each domain. The idea was for these pep-
tides to bind adjacent PDZ domains initiating protein–
protein interactions and thus crystal nucleation. As such the
linker between the predicted end of the PDZ domain and
the C-terminal peptide was varied from 2 to 6 amino acids
allowing for ﬂexibility but restraining the distance between
adjacent domains [41]. Using this approach we have now
solved 11 of the remaining 15 targets many of which have
thrown up new details regarding peptide selectivity and
structural adaptability of the PDZ domain when bound with
a peptide.
As expected for most of these domains the peptide
interaction was similar to the standard conﬁguration [42,
43] in that the side-chain of the C-terminal hydrophobic
residue (position 0) was bound in a conserved hydrophobic
pocket and that the peptide’s -2 position Ser/Thr coordi-
nates the His side chain from the aB helix. However, there
were a number of surprises of which the biggest was for
MPDZ@3 in which a class II mode of binding was
observed for a class I peptide which involved a translation
of the aB helix (Fig. 6a of [41]).
Biology area III: Structural Genomics of human
protein kinases
Kinases play an essential role in most (if not all) signalling
pathways and dysregulation has often been linked to dis-
ease. Several successful inhibitors developed to target
kinases have shown that members of this large protein
family are excellent targets for the development of drugs.
Currently protein kinases constitute about 25% of presently
pursued drug targets in industry [44–47].
There are 518 identiﬁed human protein kinases consti-
tuting 1.7% of all human genes, which have been grouped
into 10 families [48]. Despite the large number of members
and their involvement in large variety of pathways, evi-
dence points to a common single ancestral protein. As a
result, the structural features as well as key regulatory
elements and catalytic mechanism of phosphate transfer are
all well conserved. High resolution structures are therefore
essential for the rational design of potent and selective
inhibitors. Before the contribution of SG efforts, the pro-
gression of publicly available kinase structures was linear
with only 38 human kinase structures publicly available in
2004 [46]. Currently, 21 novel human kinases structures
have been released by the SGC (19 from Oxford), which
started to target this protein class in 2004. This increased
the number of unique human kinase catalytic domain
structures available in the pdb (http://www.pdb.org/pdb/
home/home.do) to 93 by the end of 2006.
Many structures, released by SG, were only distantly
related catalytic domain structures previously known and
in some cases provided the ﬁrst structural information for a
subfamily. Thus, these structures signiﬁcantly enriched the
coverage of the three dimensional structure description of
Fig. 2 The ﬂexibility of the 14-3-3 is illustrated by the superimpo-
sition of 14-3-3b (blue) with 14-3-3g (orange). The monomer
conformations of both isoforms are essentially identical on the left
hand side. However, the beta monomer on the right side has a more
open peptide binding groove and ﬂexibility at the dimeric interface
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123the kinome. Among the structures where the SGC deter-
mined the ﬁrst representative structure of a family were:
the NEK (‘‘never in mitosis’’/NIMA) family member
NEK2, the CDC2 like kinases family member CLK1 and
CLK3 as well as the ﬁrst structure of a NAK (Numb-
associated kinases) kinase MPSK1. These kinases are quite
diverse in terms of primary structure and it is therefore not
surprising that many novel structural features have been
discovered. For instance, a novel activation loop architec-
ture characterized by a large helical insert has been
discovered in the structure of MPSK1, the structures of
CLK1 and CLK3 revealed a family conserved antiparallel
beta sheet ﬂanking the kinase hinge region, and the struc-
ture of NEK2 identiﬁed a short helix following the
activation segment DFG motif that may be explored for the
development of speciﬁc inhibitors [49].
Kinases are extremely ﬂexible proteins that may adopt a
number of distinct catalytically active or inactive confor-
mations during their catalytic cycle, upon activation by
phosphorylation, or by binding of a regulatory protein, and
consequently a number of clinically successful inhibitors
have been developed to target speciﬁcally the inactive state
of kinases [50]. For example the anti-leukaemia drug I-
matinib binds selectively to the inactive state cABL
characterized by an outward conformation of the DFG
motif, a conserved tripeptide motif that ligates Mg
2+ ions
[51, 52]. It is not clear to date how many kinases are able to
adopt this conformation, which makes development of
these so-called type II inhibitors possible. In general, these
are characterized by largely improved speciﬁcity.
For the development of conventional inhibitors that
target the active state of kinases information about the
plasticity of the catalytic domain greatly facilitates the
rational design of inhibitors. Consequently it is desirable
that several structures of the same target in complex with
different ligands are available. Also here the structural
information content regarding ligand binding was signiﬁ-
cantly increased during the last three years by SG. In 2004,
only 38 human kinases had a structure available in the
public domain and only 12 publicly available structures
contained non-adenosine chemotypes [46]. From the 19
structures of kinase catalytic domains released by our
laboratory, 16 were determined in the presence of an non-
adenosine kinase inhibitor and several structures were
determined in complex with more than one inhibitor scaf-
fold (Table 2, and Fig. 3, showing PAK5 apo/inhibitor).
In addition, the SGC has supported development of
entirely new inhibitor classes exempliﬁed by co-crystal
structures with Ruthenium-half sandwich complexes.
These stable organometallic compounds are extremely
potent inhibitors for PIM1 kinases [54]. The co-crystal
structure of three inhibitors of this class showed that the
inert metal centre in this scaffold functions as a hypervalent
carbon, allowing it to occupy the binding pocket efﬁciently
with excellent shape complementarity.
Contributions of NMR to Structural Genomics
NMR as a complementary method to crystallography
for protein structure determination
The NMR spectroscopy can play an important role in
structural genomics, providing complementary information
to that obtained from X-ray crystallography. Importantly
for large-scale structural genomics projects, NMR provides
an alternative route to solving the high resolution, three-
dimensional structures of proteins that prove refractory to
crystallization. We were able to use NMR to solve the
structures of a number of relatively small protein domains
(*20 kDa) in which the domain contained at least one
ﬂexible region. The RGS domains from the regulator of
G-protein signalling proteins, RGS3, RGS10, RGS14,
RGS18, RGS20 were all very good examples of this.
Multiple constructs of these were designed, which
expressed to high yield in stable, highly soluble form yet
did not yield high quality crystals despite many months of
concerted effort. The domains were therefore expressed as
uniformly 15N-labelled proteins using standard growth
methods in E. coli, and their 15N-HSQC spectra were
recorded to assess the feasibility of structure determination
by NMR. In all cases, excellent spectral dispersion was
observed and we were able to obtain almost complete
assignment of the protein resonances. We have since
deposited the high resolution NMR structures of three RGS
domains in the PDB and the resonance assignments of four
RGS domains in the BioMagResBank (BMRB). The
structures and assignments of two further non-crystallizing
domains (Spred2 EVH1 domain and JARID1CA Bright/
ARID domain) have also been deposited, and those of
several other non-crystallizing domains ‘rescued’ by NMR
are currently underway (Table 3).
NMR as an assessment tool for the feasibility
of structure determination
Further examples where NMR has proven useful as a res-
cue strategy include particular families of signalling
domains which have a known tendency to be partially
unfolded in their unliganded states. Some examples include
certain WW domain [55, 56]. We successfully identiﬁed
peptide binding partners for a WW-tandem construct using
the SPOTs screening technique [57, 58] following which
the most strongly binding peptides were synthesized on a
large scale for NMR measurements. Although the 15N-
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were very unhopeful, the spectra of their complexes
showed signiﬁcant improvements in signal dispersion,
indicating that in the complexed form, the protein was
better folded. At this point, the protein entered our NMR
structure determination pipeline. The recording of a quick
15N-HSQC spectrum has in several cases allowed us to
rescue protein constructs with promising but borderline
behaviour, for example, proteins showing good signal
dispersion but low-medium levels of aggregation. Far from
abandoning these constructs, we took these constructs
‘back to the drawing board’ and made rational construct
improvements with the help of bio-informatic tools. Suc-
cessfully re-designed constructs were then re-screened for
fold quality by 15N-HSQC. After 2–3 iterations of this
procedure, it was often possible to reﬁne promising con-
structs sufﬁciently for structure determination. For
example, Fig. 4 shows the stepwise improvement in the
spectral properties of a hopeful, though initially problem-
atic DNA-recognition domain from the oxygenase protein,
JARID1CA. The NMR structure is now deposited (PDB
code: 2JRZ). In all of the above cases, a quick 15N-HSQC
showed immediately whether the structure determination
of a protein, having to failed to crystallize, should be
Table 2 Protein kinase structures determined by SGC
Name PDB ID Resolution [A ˚] Inhibitor name Disease link Family
CLK1 1Z57 1.70 Hymenialdisine Pot. Genetic
e CMGC
CLK3
c 2EU9 1.53 none Pot. Genetic
e CMGC
CK1c1 2CMW 1.75 Compound 52 CK1
CK1c2 2C47 2.40 5-Iodotubercidin Genetic CK1
CK1c3
d 2CHL 1.95 Triazolodiamine 1 Cancer CK1
ERK3 2I6L 2.25 none Cancer CMGC
ASK1 2CLQ 2.30 Staurosporine Inﬂammation, CV
f STE
NEK2 2JAV 2.10 SU11652 Cancer Other-NEK
PAK4
a 2CDZ 2.40 Cdk1 Inhibitor Cancer STE
PAK5 2F57 1.80 Cdk1 Inhibitor Pot. Cancer STE
PAK6 2C30 1.60 none Cancer STE
PIM1
b 1XWS 1.80 BIM I, HB1 Cancer, Inﬂammation CAMK
PIM2 2IWI 2.80 HB1 Cancer, Inﬂammation CAMK
SLK
c 2J51 2.10 Triazolodiamine 1 Pot. Cancer
e STE
MPSK1 2BUJ 2.60 Staurosporine Pot. Cancer
e Other-NAK
STK10 2J7T 2.0 SU11274 Not known STE
DAPK3 2J90 2.0 Pyridone 6 Cancer, Inﬂammation CAMK
CAMK1G 2JAM 1.7 SU11652 Not known CAMK
CAMK1D 2JC6 2.5 GSK inhibitor XIII Genetic CAMK
a PAK4 also deposited as an apo-structure in two different spacegroups: 2BVA, 2J01
b Structures with different inhibitors and substrate: PIM1: 2BIK, 2BZH,2BZI, 2BZJ, 2BZK, 2C3I, 2BIL, 2J2I; SLK: 2JA0
c CLK3 also deposited as phosphorylated protein: pdb-code: 2EXE. Detailed description of structures of targets solved in Oxford is available in
form of ‘‘iSee’’ datapacks freely downloadable on: http://www.sgc.ox.ac.uk/structures/KIN.html
d CK1c3 with different inhibitors: 2CHL, 2IZR, 2IZS, 2IZU, 2IZT
e A formal link to the disease has not been established so far but is likely
f Cardiovascular disease
Fig. 3 Superimposition of apo-PAK5 (cyan) and the PAK5 purine
complex (orange), highlighting the decomposed movements of the
glycine-rich loop (ﬂapping) and the aC helix (swinging) [53]
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123pursued or abandoned, hence reducing unnecessary attri-
tion in the structure determination pipeline.
The study of protein dynamics by NMR
The use of NMR to study the rotational correlation times
and internal dynamics of the proteins offers good explana-
tions as to why crystallization sometimes fails even for
well-folded proteins. In all of the proteins we rescued by
NMR, 15N heteronuclear NOE and 15N T1, T2 relaxation
data revealed regions of internal mobility within the pro-
teins, which would have hindered long-range order and
impaired or prevented efﬁcient crystal packing. A striking
example was the case of the RGS domain from RGS10, in
which NMR relaxation data conﬁrmed true local mobility in
a region of the domain which not only lacked in NMR
restraints, but also showed no electron density in the crystal
structure of the complex of RGS10 with G-alpha-i3 (PDB
2IHB). Comparison of mobility in RGS domains from dif-
ferent branches of the phylogenetic tree leads to clues about
their speciﬁcity and helps to guide further investigations. In
some cases, the 15N T1 and T2 data have also identiﬁed
partial dimerization in proteins that fail to crystallize, thus
explaining the latter. NMR relaxation data were in each
case conﬁrmed by analytical ultracentrifugation (AUC).
The combined information allowed us to decide whether
these proteins should be highlighted as candidates for
structure determination by NMR and to judge the best
conditions under which they should be studied.
Future and outlook
The future role that NMR will play in structural genomics
will depend heavily on the continued development and
implementation of new, faster methods of data acquisition,
processing, resonance- and NOE-assignment and structure
determination and reﬁnement. These topics have been
covered extensively in other reviews; for a concise sum-
mary see [59] and references therein. The potential time
gains that could be gained from these methods make high
throughput structure determination by NMR a realistic
possibility for the future.
Structural bioinformatics and rationalisation of
experimental results
A crystal structure of a protein in absence of ligand or
substrate may not always provide insight on reaction me-
chinasms or speciﬁcity. Ideally, such information can be
derived from additional structures with bound ligands. In
the absence of such co-crystals, interpretation of results
from biochemical assays and compound screening is more
speculative. However, these results can be rationalised with
in silico docking of potential ligands into the active site of
unliganded protein structures. An example illustrating this
point is the analysis of the DHRS10 structure [20]. Anal-
ysis of the different docking poses can be correlated with
experimental results, allowing direct visualisation of the
putative protein–ligand complex. With these results, fur-
ther modiﬁcations of the enzyme can be suggested more
reliably, allowing a faster progress towards the complete
elucidation of the mechanistics.
Dissemination of structural genomics data and
knowledge
Structural genomics produces a wealth of information of
different types: DNA and protein seqeuences, biochemical
information, coordinates of crystal structures, and structural
Table 3 Deposited NMR structures and assignments
Gene PDB deposition Resonance assignment
deposition
RGS3 – BMRB-15178
RGS10 2I59 BMRB-7272
RGS14 2JNU BMRB-15128
RGS18 2OWI BMRB-7106
SPRED2 2JP2 BMRB-5939
JARID1CA 2JRZ BMRB-15348
Fig. 4 Visible improvement in
quality of 15N-HSQC spectra
over two rounds of iterative
construct re-design for the
JARID1CA Bright/ARID
domain. The leftmost (initial)
construct shows potential. The
structure of the ﬁnal construct
on the far right was determined
by NMR (PDB code: 2JRZ)
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public databases, predominantly the PDB, in addition to
publication in journals. This form of data distribution does
not adequately disseminate the full information to a wide
scientiﬁc audience. The ﬁrst issue is the fragmentation of
data between different formats. A user may have to read text
information in a journal paper, which may include a few
two-dimensional Figures; then download a PDB structure
ﬁle and image with a separate application; and then perform
analysis and alignment of data from, say, SNP database
using alignment software. The second issue is that non-
structural biologists do not routinely access PDB ﬁles,
especially of structures that were not published in pubmed-
indexed journals.
We have approached this challenge by developing a new
intuitive dissemination concept in conjunction with Mol-
soft LLC (San Diego, CA) [60]. This concept, (which we
denoted iSee) integrates all the information associated with
any given target solved by SGC into a small, self-contained
ﬁle, annotated by the authors (Fig. 5). The ﬁle not only
allows the direct visualisation of text information, but also
offers an interactive visualisation feature fully integrated to
the structural data being presented. At any stage, the
annotation written by the expert can be coupled with an
interactive molecular graphics scene. Transition between
each anotated viewpoint is fully animated on-the-ﬂy, to
convey a sense of three-dimensionality which is vital for
the user to grasp the spatial relationship between different
features on a structure.
Each of these ﬁles (called an iSee datapack), as well as
the software needed to visualise them (ICM-Browser) are
available for free download from our website (http://www.
sgc.ox.ac.uk/iSee).
We also maintain and curate each of these ﬁles by
revising each datapack quarterly to ensure that all the
recently disclosed information is added (either by ourselves
through follow-up experiments or by external collaborators
working on the same targets). Each of the datapacks has a
built-in automated updating function that can be executed
on user’s request.
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